Biocardia announces issuance of two patents related to technology that guides interventional therapies

Sunnyvale, calif., april 04, 2023 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies.
BCDA Ratings Summary
BCDA Quant Ranking